We focus on delivering solutions to patients and healthcare professionals via medicines and services for central nervous system disorders with a strong emphasis on multiple sclerosis, and other neurodegenerative disorders.
We concentrate on supporting the NHS in managing long-term conditions like multiple sclerosis and Parkinson's disease. Our aim is to work in partnership to develop joined-up care through Joint Working projects, to improve patient outcomes and enhance patient experience, and also to offer value for money. That might be through medicines optimisation, quality improvement, pathway redesign or improvement, innovation or identifying cost efficiencies.
Within Teva’s CNS medicines we have Copaxone® (glatiramer acetate) injection for the treatment of relapsing forms of multiple sclerosis and is available as a 20mg daily injection or as a 40mg three times weekly injection, and Azilect® (rasagiline) tablets which is for the treatment of the symptoms of Parkinson’s disease.
Multiple sclerosis (MS) is the most common cause of neurological disability in young adults and affects more than 2.5 million people worldwide.1 MS affects around 100,000 people in the UK.2 In the majority of patients, the disease is of the relapsing-remitting form (RRMS),3 which is manifested by relapses and slow progression of the disease that can affect the functioning of multiple systems.
Our Joint Working projects help the NHS and healthcare professionals deliver improved patient outcomes. Our Joint Working projects are available on our Joint Working pages.
To discuss potential Joint Working opportunities with Teva within CNS you can contact us and a representative from Teva will be in touch.
1 https://www.mstrust.org.uk/a-z/prevalence-and-incidence-multiple-sclerosis [accessed 15.03.16].
2 http://www.mssociety.org.uk/what-is-ms [accessed 15.03.16].
3 https://www.nice.org.uk/guidance/cg186/chapter/introduction [accessed 15.03.16].
4 Copaxone® (glatiramer acetate) 20mg Summary of Product Characteristics.
5 Copaxone® (glatiramer acetate) 40mg Summary of Product Characteristics.
6 Khan O et al. Ann Neurol 2013: 73; 705–713.
7 http://www.pdf.org/en/parkinson_statistics [accessed 15.03.16].
8 http://www.parkinsons.org.uk/content/what-parkinsons [accessed 15.03.16].
9 Azilect® (rasagiline) Summary of Product Characteristics.
To access this section of the Teva UK Limited website you need to be a member of the healthcare profession
because the materials included in this area of our website are specifically prepared for that audience
To understand why that is - please visit: Working in a regulated environment
Please click on the appropriate button below to confirm that you are healthcare professional.
If you are not a healthcare professional, you will be taken to an area of the website that is appropriate for you.